Oncomine Myeloproliferative Neoplasm MPN Panel Test
Comprehensive Genetic Analysis for Blood Cancer Diagnosis
The Oncomine Myeloproliferative Neoplasm MPN Panel Test represents a cutting-edge molecular diagnostic approach for identifying genetic mutations associated with myeloproliferative neoplasms and related hematologic malignancies. This comprehensive next-generation sequencing panel provides clinicians with essential genetic information to guide accurate diagnosis, prognosis assessment, and personalized treatment strategies for patients with suspected or confirmed blood cancers.
What Does the MPN Panel Test Measure?
This advanced genetic panel utilizes next-generation sequencing technology to analyze 26 critical genes and multiple fusion genes implicated in myeloproliferative neoplasms:
Core Gene Mutations Analyzed:
- Driver Mutations: JAK2, CALR, MPL – Essential for MPN diagnosis
- Epigenetic Regulators: ASXL1, DNMT3A, EZH2, TET2 – Impact disease progression
- Signaling Pathway Genes: CBL, FLT3, KIT, NRAS, NF1 – Influence cell growth and survival
- Tumor Suppressors: TP53, RUNX1 – Critical for genomic stability
- Spliceosome Components: SF3B1, SRSF2, U2AF1, ZRSR2 – Affect RNA processing
- Transcription Factors: ETV6, IKZF1, STAG2 – Regulate gene expression
Fusion Gene Analysis:
- ETV6 rearrangements
- JAK2 fusions
- KMT2A translocations
- RUNX1 abnormalities
Who Should Consider This Test?
The Oncomine MPN Panel is recommended for patients presenting with:
Clinical Symptoms:
- Unexplained elevated blood counts (erythrocytosis, thrombocytosis, leukocytosis)
- Splenomegaly or hepatomegaly without clear cause
- Constitutional symptoms: fatigue, night sweats, weight loss, fever
- Thrombotic or hemorrhagic complications
- Pruritus or erythromelalgia
- Bone pain or early satiety
Patient Groups:
- Individuals with suspected myeloproliferative neoplasms
- Patients requiring differential diagnosis between MPN subtypes
- Those with unexplained bone marrow fibrosis
- Cases where standard JAK2 testing is negative but clinical suspicion remains high
- Patients being evaluated for targeted therapy options
Benefits of the Oncomine MPN Panel Test
Comprehensive Diagnostic Power
Unlike single-gene tests, this panel provides a complete genetic profile in a single analysis, eliminating the need for sequential testing and reducing diagnostic delays.
Personalized Treatment Guidance
Genetic results help identify patients who may benefit from specific targeted therapies, including JAK inhibitors and other molecularly targeted agents.
Prognostic Information
Certain mutations (ASXL1, EZH2, SRSF2, IDH1/2) are associated with higher-risk disease and may influence treatment intensity decisions.
Monitoring Disease Evolution
The comprehensive baseline genetic profile enables monitoring of clonal evolution and early detection of disease transformation to acute myeloid leukemia.
Understanding Your Test Results
Positive Results
A positive result indicates the presence of one or more genetic mutations associated with myeloproliferative neoplasms. Your hematologist will interpret these findings in the context of your clinical presentation and other laboratory results to establish a definitive diagnosis.
Negative Results
A negative result suggests that no mutations in the tested genes were detected. However, this does not completely rule out MPN, as rare mutations outside the panel or non-genetic factors may be involved.
Variant of Uncertain Significance (VUS)
Some genetic changes may be classified as VUS, meaning their clinical significance is currently unknown. These findings require careful clinical correlation and may be reclassified as more data becomes available.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Oncomine Myeloproliferative Neoplasm MPN Panel Test | $1024 USD | $1138 USD |
Turnaround Time
- Sample Submission: By 1st or 16th of every month
- Report Delivery: 15th or 30th of same month
Sample Requirements
- Sample Type: 3 mL (2 mL minimum) whole blood OR bone marrow
- Collection Tube: 1 Lavender top (EDTA) tube
- Shipping: Refrigerated – DO NOT FREEZE
- Required Documentation: Duly filled NGS Test Requisition Form (Form 40) is mandatory
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more cities nationwide. Our network ensures accessible, high-quality genetic testing for patients throughout the country.
Take Control of Your Health Today
Early and accurate genetic testing is crucial for effective management of myeloproliferative neoplasms. The Oncomine MPN Panel provides the comprehensive genetic information needed to guide your treatment journey and optimize outcomes.
Ready to schedule your test? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Our team is available to answer your questions and help you understand the testing process.
Don’t wait to get the answers you need for personalized cancer care. Early detection and precise genetic characterization can make a significant difference in your treatment approach and long-term outcomes.
